COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up
by
Mateusz Puchalski
1, 
Halszka Kamińska
1,
Marta Bartoszek
2,
Michał Brzewski
2 and
Bożena Werner
1,* 1
Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, 02-091 Warsaw, Poland
2
Department of Pediatric Radiology, Medical University of Warsaw, 02-091 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(6), 3456; https://doi.org/10.3390/ijerph19063456
Submission received: 20 January 2022
/
Revised: 6 March 2022
/
Accepted: 11 March 2022
/
Published: 15 March 2022
Abstract
:Presently, the whole globe is struggling the tough challenge of the COVID-19 pandemic. Vaccination remains the most effective and safe COVID-19 weapon for adults and in the paediatric population. Aside from possible mild and moderate post-vaccination side effects, more severe side effects may occur. We retrospectively analysed a group of 5 teenagers aged from 15 to 17 years with obesity/overweight (BMI ranging from 24.8 to 30) who presented typical myocarditis symptoms following the first or second dose (3 and 2 patients, respectively) of the COVID-19 vaccine. In the whole study group, a significant increase in troponin serum concentration was observed (1674–37,279.6 ng/L) with a further quick reduction within 3–4 days. In all patients, ST segments elevation or depression with repolarisation time abnormalities in electrocardiography were noticed. Chest X-ray results were within normal limits. Echocardiography showed normal left ventricular diameter (47–56.2 mm) with ejection fraction between 61–72%. All patients were diagnosed with myocarditis based on cardiac magnetic resonance (CMR) imaging. During further hospitalisation, swift clinical improvement was notable. Follow-up in the whole study group was obtained after 106–134 days from initial CMR, revealing no myocarditis symptoms, proper troponin level, and no ECG or echocardiographic abnormalities. At the same time, persistent myocardium injury features were detected in the whole study group, including ongoing myocarditis. COVID-19-vaccine-induced myocarditis seems to be a mild disease with fast clinical recovery, but the complete resolution of the inflammatory process may last over 3 months. Further follow-up and investigation for assessing subsequent implications and long-term COVID-19-vaccine-induced myocarditis is required.
Keywords:
COVID-19; vaccine; myocarditis; teenagers; Cardiology; Paediatrics; cardiac magnetic resonance1. Introduction
The worldwide spread of the coronavirus (COVID-19) pandemic has caused over 5 million deaths across the globe [1]. For the time being, in European countries, two messenger RNA (mRNA) vaccines (Pfizer-BioNTech and Moderna) are approved to reduce the risk, severity, and transmission of the COVID-19 disease in the 12–18 years age group [2]. Beyond mild and moderate post-vaccination side effects, more severe side effects, such as myocarditis, have also been noted [3]. According to the Vaccine Adverse Event Report System (VAERS), 691 cases of COVID-19 vaccine side effects, diagnosed as myocarditis in the aforementioned population, have been reported to date [4]. In our study, we present the clinical characteristics of 5 teenagers hospitalized in the Paediatric Cardiology Department of University Hospital due to acute myocarditis following Pfizer-BioNTech vaccination. Our studied group is one of the first and currently the biggest population with further long-term follow-up with particular emphasis on CMR imaging evaluation in the whole study group.
2. Materials and Methods
Our single-centre retrospective study comprised five teenagers hospitalized in the Paediatric Cardiology and General Paediatrics Department from July to August 2021 who were assessed by signs and clinical symptoms, laboratory data of cardiological biomarkers (troponin serum concentration and NT-proBNP), electrocardiography, echocardiography, and cardiac magnetic resonance (CMR). Follow-ups were carried out 106–134 days after initial CMR.
3. Results
All patients were white male teenagers (age range 15–17 years) with no underlying medical conditions on admission. Four patients were obese, and one was overweight, according to the World Health Organization’s body mass index [5]. None of them had a positive medical history for previous COVID-19 infection. All patients received the Pfizer-BioNTech mRNA vaccine, 3 of them developed symptoms after the first dose and 2 developed symptoms after the second dose. All presented with symptoms 2–8 days after immunization, with sudden onset sharp and retrosternal chest pain radiating to the left shoulder in patient 5. All but one (patient 4) had body temperature rise, one (patient 2) reported diarrhoea and shoulder pain at the injection spot, and one (patient 4) was affected with dry cough. Symptom duration ranged from 3 to 6 days (Table 1).
On admission, all patients were in a good condition with stable vitals. Each of them was tested for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR swab test with negative results in the whole group. Other viral and bacterial serologies testing included the most common respiratory tract, neurological, and digestive system pathogens, and were all negative. Blood tests revealed significant increases in highly sensitive troponin I serum concentration in all patients with further rapid, gradual normalization. Furthermore, moderate rise of N-terminal pro-B type natriuretic peptide (NT-proBNP), and C-reactive protein (CRP) plasma concentration was noticed in patients 1 and 4 and patients 1, 2, 3, and 5, respectively, with normalization above mentioned parameters before hospital discharge (Table 1).
Electrocardiogram (ECG) pattern varied, but in all cases, characteristic features for acute myocardium injury, including ST segments elevation or depression, and repolarisation time abnormalities were observed (Table 2). Chest X-rays in all patients revealed no abnormalities. In all patients, transthoracic echocardiography (TTE) showed normal size and function of the left ventricle to the left ventricular internal diameter in diastole (LVIDd) and ejection fraction (EF) within normal limits.
All patients underwent cardiovascular magnetic resonance imaging (CMR) between 6 and 37 days after vaccine immunisation to confirm and evaluate extend of nonischemic myocardium injury and oedema according to updated 2018 Lake Luise Myocarditis Criteria [6]. The obtained CMR images revealed hyperintense signal of oedema partly overlapping with late gadolinium enhancement (LGE) in particular LV segments and thus fulfilling Lake Louise Criteria for myocarditis in the whole group (Table 2). In all patients left and right ventricular function was within normal limits and no pericardial involvement was detected in either the ECHO or the CMR imaging. Considering good general condition with stable vitals, none of the patients qualified for endomyocardial biopsy.
During further hospitalization, all patients were treated with angiotensin-converting enzyme inhibitors (ACEI), and were discharged in stable clinical condition, with no alarming symptoms after 10–16 days of hospital observation and recommendation of a further 3-month follow-up.
Three months after hospital discharge (with the exception of patient 5 with follow-up appointment postponed for one month due to moderate infectious symptoms) renewed evaluation of general condition and additional tests were performed, revealing no symptoms similar to admission time in all except one (patient 4, who reported single, sharp episodes of chest pain lasting for few seconds), normal highly sensitive troponin I serum concentration, regular pattern of ECG in all but one (patient 3, preserved flat T wave in leads V5 and V6), no arrhythmias in 24 h Holter–ECG monitoring, and no abnormalities in TTE. All the patients at this point underwent control CMR (106–134 days after initial CMR). In contrast to other tests, in all patients, CMR imaging showed persistent features of myocardial injury: active inflammatory process (T2-weighted images of myocardium oedema coexisting with LGE in T1-weighted mapping patients 1 and 4) or persistent LGE without oedema. In all patients, ACEI treatment was continued and further treatment was planned (Table 3).
4. Discussion
Vaccination against COVID-19 undoubtedly remains the most effective and proved form of COVID-19 elimination in all population groups [7,8]. Moderna and Pfizer-BioNtech mRNA vaccines are distinguished by their high efficacy and safety in children [2,9]. It should be noted that COVID-19 immunisation carries the possibility of mild–moderate side effects (e.g., pain in injection site, fever, malaise occurring and resolving within 1–2 days). In rare cases, more severe adverse effects, even including life-threatening ones, such as myocarditis, may occur [3,10]. It is worth mentioning that post-vaccination myocarditis has been also widely reported after many other vaccines, including influenza, hepatitis B virus, and tetanus [11,12]. The strongest case–effect relation between immunisation and myocardium injury were proven for smallpox vaccination. Endomyocardial biopsy with further pathomorphology study in those cases showed immunological etiology rather than direct myocardium injury [13,14]. As can be seen from the available literature, COVID-19 infection may also provoke subsequent immoderate host immune response [15], so it is possible that, in some rare cases, the same mechanism may be triggered by vaccine administration. The direct mechanism of myocardium injury following the COVID-19 vaccine remains unclear and further investigations are needed [16].
In our study, with a homogeneous teenager group, four patients were described as obese, and one as overweight, according to the WHO body mass index. This may be considered an interesting fact in the light of the recent review by Bortolini et al., according to which, physical inactivity and obesity are factors decreasing the vaccine’s efficacy and immune response [17]. However, obesity itself is a known risk factor of hyperimmune reactions, which may be at least partially responsible for myocarditis in our group. Additionally, quick general condition and symptoms improvement correlated with rapid and prominent decrease in troponin I serum concentration was observed (within 3–4 days after peak, Table 1), and ECG normalization was observed within the whole group.
Similar patterns have been presented in the current literature. In most reported cases, myocarditis after COVID-19 immunisation affects male adolescents or young adults between 12 and 24 years, most commonly after the second dose of the mRNA-type vaccine [18]. The majority of patients presented typical myocarditis symptoms—chest pain, shortness of breath and, fever—within 2–4 days after administration and also with swift improvement of symptoms and general condition. Most patients did not require any advanced therapy or additional procedures [18,19,20,21].
In CMR, the location of myocardial lesions during the acute period (both LGE and oedema) was, in our group, similar to patterns reported so far in the literature (basal and mid-lateral segments of left ventricle) [22,23,24,25]. Despite of significant difference of peak troponin between patients 1, 2, and 3 and patients 4 and 5, there was no correlation between troponin level and CMR findings. The extend of myocarditis in all patients, estimated on the basis of myocarditis involved left ventricle segments, was comparable in all patients. Moreover, elevated troponin concentration, before the outbreak of the COVID-19 pandemic, was recognised as a poor prognostic marker in adult patients with acute coronary syndrome, as well as in children with acute fulminant myocarditis [26]. Contrarily, according to a retrospective by Matsubara et al., longitudinal cohort study troponin concentration seems to not be correlated with worse clinical implications in children with paediatric inflammatory multisystem syndrome temporary, associated with SARS-CoV-2 (PIMS-TS) [27]. In view of the above, and the supposed immune mechanism of PIMS-TS and COVID-19-vaccine-related myocarditis, the troponin level appears to not reflect the CMR findings in wither of the abovementioned groups. This issue still requires further analysis.
Interestingly, the mild and transient clinical course of the disease was not illustrated by the CMR results obtained after 3 months. In all our patients, persistent abnormalities were found, including an active inflammatory process in two of them. To our knowledge, this is one of the first publications highlighting this problem and, so far, the present study is based on the largest number of cases.
In August 2021, Supriya et al. described persistent CMR abnormalities (LGE without oedema) in 2 patients with myocarditis after COVID-19 vaccine in whom CMR was performed after 66 and 71 days from initial CMR [28].
In our group, the active inflammatory process lasted longer. In two patients, after three months, CMR showed persistent oedema with LGE, and in only three LGE.
On the other hand, the most current data from the literature suggest that children with acute myocarditis not related to the vaccination also show CMR abnormalities (mostly LGE) months after full clinical recovery. Seven months after the initial CMR, approximately one third of children still present CMR abnormalities suggestive of active inflammatory processes, and only one third can be described as exhibiting total normalization [29]. Moreover, about half of the patients after myocarditis recovery may present myocardium scarring (consistent with LGE in CMR), which could transform into the trigger spots for even life-threatening rhythm disturbances [30].
In view of the above, our study, with special emphasis on CMR imaging follow-up, symbolises one step forward in obtaining insights into the course and recovery pattern of COVID-19-vaccine-induced myocarditis. Both further studies and longer follow-up of patients should be considered to assess ensuing implications of COVID-19-vaccine-connected myocardium injury.
5. Conclusions
COVID-19-vaccine-induced myocarditis seems to be a mild disease with a fast clinical recovery.
The complete resolution of the inflammatory process may last longer.
Based on CMR findings in the study group, the myocardium injury may persist longer than three months from the initial CMR.
Longer follow-up and further investigation for assessing subsequent implications and long-term COVID-19-vaccine-induced myocarditis are required.
Author Contributions
Conceptualization, B.W. and M.P.; data curation, M.P., M.B. (Marta Bartoszek) and M.B. (Michał Brzewski); formal analysis, M.P., H.K. and B.W.; writing—original draft preparation, M.P.; writing—review and editing, B.W., H.K., M.P. and M.B. (Michał Brzewski); supervision, B.W. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Ethical review and approval were waived due to the retrospective nature of the study basing on already available data.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data will be made available by the corresponding author, upon reasonable request.
Conflicts of Interest
Authors declare no conflict of interest.
References
- WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 1 February 2022).
- Frenck, R.W., Jr.; Klein, N.P.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; Perez, J.L.; Walter, E.B.; Senders, S.; Bailey, R.; et al. C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents. N. Engl. J. Med. 2021, 385, 239–250. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html (accessed on 1 February 2022).
- Vaccine Adverse Event Reporting System. Available online: https://vaers.hhs.gov/ (accessed on 1 February 2022).
- Mitchell, E.A.; Stewart, A.W.; Braithwaite, I.; Murphy, R.; Hancox, R.J.; Wall, C.; Beasley, R. ISAAC Phase Three Study Group. Factors associated with body mass index in children and adolescents: An international cross-sectional study. PLoS ONE 2018, 13, e0196221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gutberlet, M.; Lücke, C. Original versus 2018 Lake Louise Criteria for Acute Myocarditis Diagnosis: Old versus New. Radiol. Cardiothorac. Imaging 2019, 1, e190150. [Google Scholar] [CrossRef] [PubMed]
- Lin, D.Y.; Zeng, D.; Mehrotra, D.V.; Corey, L.; Gilbert, P.B. Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. Clin. Infect. Dis. 2021, 73, 1540–1544. [Google Scholar] [CrossRef] [PubMed]
- Rauf, A.; Abu-Izneid, T.; Olatunde, A.; Ahmed Khalil, A.; Alhumaydhi, F.A.; Tufail, T.; Shariati, M.A.; Rebezov, M.; Almarhoon, Z.M.; Mabkhot, Y.N.; et al. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int. J. Environ. Res. Public Health 2020, 17, 8155. [Google Scholar] [CrossRef] [PubMed]
- Ali, K.; Berman, G.; Zhou, H.; Deng, W.; Faughnan, V.; Coronado-Voges, M.; Ding, B.; Dooley, J.; Girard, B.; Hillebrand, W.; et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N. Engl. J. Med. 2021, 385, 2241–2251. [Google Scholar] [CrossRef]
- Rutkowski, K.; Mirakian, R.; Till, S.; Rutkowski, R.; Wagner, A. Adverse reactions to COVID-19 vaccines: A practical approach. Clin. Exp. Allergy 2021, 51, 770–777. [Google Scholar] [CrossRef] [PubMed]
- Mei, R.; Raschi, E.; Forcesi, E.; Diemberger, I.; De Ponti, F.; Poluzzi, E. Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. Int. J. Cardiol. 2018, 273, 183–186. [Google Scholar] [CrossRef] [PubMed]
- Su, J.R.; McNeil, M.M.; Welsh, K.J.; Marquez, P.L.; Ng, C.; Yan, M.; Cano, M.V. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. Vaccine 2021, 39, 839–845. [Google Scholar] [CrossRef] [PubMed]
- Engler, R.J.; Nelson, M.R.; Collins, L.C., Jr.; Spooner, C.; Hemann, B.A.; Gibbs, B.T.; Atwood, J.E.; Howard, R.S.; Chang, A.S.; Cruser, D.L.; et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS ONE 2015, 10, e0118283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murphy, J.G.; Wright, R.S.; Bruce, G.K.; Baddour, L.M.; Farrell, M.A.; Edwards, W.D.; Kita, H.; Cooper, L.T. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 2003, 362, 1378–1380. [Google Scholar] [CrossRef]
- Kawakami, R.; Sakamoto, A.; Kawai, K.; Gianatti, A.; Pellegrini, D.; Nasr, A.; Kutys, B.; Guo, L.; Cornelissen, A.; Mori, M.; et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2021, 77, 314–325. [Google Scholar] [CrossRef] [PubMed]
- Mehmood, I.; Ijaz, M.; Ahmad, S.; Ahmed, T.; Bari, A.; Abro, A.; Allemailem, K.S.; Almatroudi, A.; Tahir ul Qamar, M. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. Int. J. Environ. Res. Public Health 2021, 18, 1626. [Google Scholar] [CrossRef]
- Bortolini, M.J.S.; Petriz, B.; Mineo, J.R.; Resende, R.d.O. Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups. Int. J. Environ. Res. Public Health 2022, 19, 1853. [Google Scholar] [CrossRef] [PubMed]
- Abu Mouch, S.; Roguin, A.; Hellou, E.; Ishai, A.; Shoshan, U.; Mahamid, L.; Zoabi, M.; Aisman, M.; Goldschmid, N.; Berar Yanay, N. Myocarditis following COVID-19 mRNA vaccination. Vaccine 2021, 39, 3790–3793. [Google Scholar] [CrossRef] [PubMed]
- Kwan, M.Y.W.; Chua, G.T.; Chow, C.B.; Tsao, S.S.L.; To, K.K.W.; Yuen, K.Y.; Lau, Y.L.; Ip, P. mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med. J. 2021, 27, 326–327. [Google Scholar] [CrossRef] [PubMed]
- Truong, D.T.; Dionne, A.; Muniz, J.C.; McHugh, K.E.; Portman, M.A.; Lambert, L.M.; Thacker, D.; Elias, M.D.; Li, J.S.; Toro-Salazar, O.H.; et al. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. Circulation 2022, 145, 345–356. [Google Scholar] [CrossRef] [PubMed]
- Oster, M.E.; Shay, D.K.; Su, J.R.; Gee, J.; Creech, C.B.; Broder, K.R.; Edwards, K.; Soslow, J.H.; Dendy, J.M.; Schlaudecker, E.S.; et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA 2022, 327, 331–340. [Google Scholar] [CrossRef]
- Patel, Y.R.; Louis, D.W.; Atalay, M.; Agarwal, S.; Shah, N.R. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: A case series. J. Cardiovasc. Magn. Reson. 2021, 23, 101. [Google Scholar] [CrossRef]
- Dickey, J.B.; Albert, E.; Badr, M.; Laraja, K.M.; Sena, L.M.; Gerson, D.S.; Saucedo, J.E.; Qureshi, W.; Aurigemma, G.P. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc. Imaging. 2021, 14, 1862–1863. [Google Scholar] [CrossRef]
- Rosner, C.M.; Genovese, L.; Tehrani, B.N.; Atkins, M.; Bakhshi, H.; Chaudhri, S.; Damluji, A.A.; de Lemos, J.A.; Desai, S.S.; Emaminia, A.; et al. Myocarditis Temporally Associated With COVID-19 Vaccination. Circulation 2021, 144, 502–505. [Google Scholar] [CrossRef]
- Marshall, M.; Ferguson, I.D.; Lewis, P.; Jaggi, P.; Gagliardo, C.; Collins, J.S.; Shaughnessy, R.; Caron, R.; Fuss, C.; Corbin, K.J.E.; et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021, 148, e2021052478. [Google Scholar] [CrossRef] [PubMed]
- Al-Biltagi, M.; Issa, M.; Hagar, H.A.; Abdel-Hafez, M.; Aziz, N.A. Circulating cardiac troponins levels and cardiac dysfunction in children with acute and fulminant viral myocarditis. Acta Paediatr. 2010, 99, 1510–1516. [Google Scholar] [CrossRef] [PubMed]
- Matsubara, D.; Chang, J.; Kauffman, H.L.; Wang, Y.; Nadaraj, S.; Patel, C.; Paridon, S.M.; Fogel, M.A.; Quartermain, M.D.; Banerjee, A. Longitudinal Assessment of Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children Associated With COVID-19 Infections. J. Am. Heart. Assoc. 2022, 11, e023251. [Google Scholar] [CrossRef]
- Jain, S.S.; Steele, J.M.; Fonseca, B.; Huang, S.; Shah, S.; Maskatia, S.A.; Buddhe, S.; Misra, N.; Ramachandran, P.; Gaur, L.; et al. COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics 2021, 148, e2021053427. [Google Scholar] [CrossRef] [PubMed]
- Małek, Ł.A.; Kamińska, H.; Barczuk-Falęcka, M.; Ferreira, V.M.; Wójcicka, J.; Brzewski, M.; Werner, B. Children With Acute Myocarditis Often Have Persistent Subclinical Changes as Revealed by Cardiac Magnetic Resonance. J. Magn. Reson. Imaging. 2020, 52, 488–496. [Google Scholar] [CrossRef] [PubMed]
- Grigoratos, C.; Di Bella, G.; Aquaro, G.D. Diagnostic and prognostic role of cardiac magnetic resonance in acute myocarditis. Heart Fail. Rev. 2019, 24, 81–90. [Google Scholar] [CrossRef] [PubMed]
Table 1.
General information, laboratory tests, treatment, length of hospital stays.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
| Sex | M | M | M | M | M |
| Age | 15 | 17 | 17 | 17 | 17 |
| BMI kg/m2 (WHO centiles) | 27 (95), obesity | 25.8 (95), obesity | 30 (97), obesity | 30 (99), obesity | 24.8 (89), overweight |
| Vaccine name | Pfizer-BioNTech | Pfizer-BioNTech | Pfizer-BioNTech | Pfizer-BioNTech | Pfizer-BioNTech |
| Dose number | 2 | 2 | 1 | 1 | 1 |
| Time (days) from vaccine to symptoms | 2 | 2 | 2 | 3 | 23 |
| Symptom description | Central, non-radiating chest pain, fever (37.8), | Central, non-radiating chest pain, fever (38.5), shoulder pain at the injection site, diarrhoea | Left-sided, non-radiating chest pain, fever (39), dry cough, | Left-sided, non-radiating chest pain | Central, radiating to the left shoulder chest pain, sore throat, fever (39) |
| Symptom duration (days) | 3 | 3 | 4 | 4 | 6 |
| Laboratory tests: | |||||
| COVID-19 PCR test at presentation | Negative | Negative | Negative | Negative | Negative |
| COVID-19 antibodies | |||||
| IgA and IgM class | Negative | Negative | Positive | Positive | Negative |
| IgG class | Positive | Positive | Positive | Positive | Positive |
| Troponin concentration | |||||
| Peak | 14,218.4 | 37,279.6 | 10,450.3 | 1895.2 | 1674 |
| Next troponin level (days after peak) | 102 (4) | 354.1 (3) | 327.0 (3) | 325 (3) | 360.0 (3) |
| Discharge (days after peak) | 12.4 (9) | 20.9 (13) | 18.5 (14) | 8.5 (12) | 1.5 (11) |
| Others: | |||||
| NT-proBNP | 269 | 27 | 50 | 259 | 391 |
| CRP | 3.0 | 3.9 | 3.9 | 0.7 | 40 |
| White blood cell count | 6.8 | 10.02 | 7.78 | 8.02 | 9.95 |
| Viral and bacterial serological tests | |||||
| Respiratory tract panel 1 | Negative | Negative | Negative | Negative | Negative |
| Neurological panel 2 | Negative | Negative | Negative | Negative | Negative |
| Rotavirus and adenovirus | Not obtained | Negative | Negative | Negative | Negative |
| Treatment | Lisinopril | Enalapril | Ramipril | Ramipril | Ramipril |
| Length of hospital stay (days) | 10 | 13 | 16 | 12 | 11 |
NT-proBNP, pq/mL, (N < 125); Troponin, ng/L (N < 19.0); CRP mg/dL, (N: 0.0–1.0); White blood cell count (N: 4–10 × 103/uL). 1 Respiratory tract panel—nasopharyngeal swab; PCR testing—adenovirus, mycoplasma pneumoniae, coronaviruses (HKU1, NL63, OC43, 229E), human metapneumovirus, human rhino/enterovirus, influenzas viruses (A, A/H1, A/H1-2009, A/H3, B, MERS), parainfluenza viruses (1, 2, 3, 4), RSV, SARS-CoV-2, Bordetella pertussis, Bordetella parapertusis, Chlamydophila pneumoniae. 2 Neurological panel, blood sample PCR testing—CMV, EBV, HSV1, HSV2, HSV6, HHV6, HHV7, Enterovirus, Adenovirus, Parechovirus, Parvovirus, ParvovirusB19.
Table 2.
Imaging tests.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
| Imaging Tests | |||||
| Chest X-ray | Unchanged | Unchanged | Unchanged | Unchanged | Unchanged |
| Electrocardiogram | ST elevation in I, II, V5–V6, | ST elevation in II, III, aVF, V5–V6 | ST elevation in V3–V4 | ST elevation in II, III, aVF | ST elevation in V4–V6 |
| ST depression in V1–V2 | Negative T wave in I–III, aVL, aVF, V4–V6, | ||||
| Echocardiography | |||||
| %EF | 64 | 72 | 61 | 62 | 68 |
| Left Ventricular End Diastolic Diameter (mm) | 54.5 | 47–50 | 45.9 | 56.2 | 55 |
| Regional wall motion changes and pericardial effusion | No changes | No changes | No changes | No changes | No changes |
| CMR imaging | |||||
| Time from vaccine to CMR (days) | 8 | 6 | 10 | 11 | 37 |
| Myocardial oedema (T2 mapping), segment of LV | All basals | All basals, | Mid: inferior and inferolateral | All basals | All basals |
| Mid: anterolateral, inferolateral | Mid: anterolateral, inferolateral, | Mid: inferior, inferolateral | Mid: inferior, inferolateral | ||
| inferoapical: lateral and inferior | Apical: inferior, lateral | ||||
| Nonischemic Myocardial Injury (LGE, T1-weight mapping) | |||||
| Subepicardial and intraventricular LGE in segments | Basal: anterolateral, inferolateral, inferior | All basals | No changes | No changes | All basals, |
| Mid: inferolateral, inferiors | Mid: inferolateral | ||||
| Apical: inferior and lateral | |||||
| Only subepicardial LGE in segments | Mid: anterolateral, inferolateral | All basals | Basal: inferior and inferolateral | All basals | All basals |
| Mid: anterolateral | Mid: inferior, inferolateral | Mid: anterolateral | |||
| Apical: inferior and lateral | |||||
Troponin, ng/L (N < 19.0).
Table 3.
Follow-up 106–134 days from initial CMR.
| Follow-Up | |||||
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
| Follow-Up | |||||
| Troponin, ng/L (<19.0) | 4.7 | 1.5 | <1.5 | 2.3 | Not obtained |
| ECG findings | No changes | No changes | Flat T wave in V5–V6 | No changes | No changes |
| Echocardiography | |||||
| %Ejection Fraction | 61 | 66 | 77 | 66 | 77 |
| Regional wall motion changes | No changes | No changes | No changes | No changes | No changes |
| Pericardial effusion | No changes | No changes | No changes | No changes | No changes |
| CMR imaging | |||||
| Time from initial CMR (days) | 106 | 119 | 112 | 112 | 134 |
| Myocardial oedema (T2 mapping), segment of LV | All basals | No oedema | No oedema | Basal inferolateral | No oedema |
| Mid: anterolateral, inferolateral | |||||
| All inferior | |||||
| Nonischemic Myocardial Injury (Late gadolinium enhancement LGE) | |||||
| Subepicardial and intraventricular LGE in segments: | Basal: anterolateral, inferolateral, inferior | All basals, | No changes | No changes | All basals |
| Mid: inferolateral, | Mid: inferolateral, inferior | ||||
| All inferior | |||||
| Apical lateral | |||||
| Only subepicardial LGE in segments: | No changes | No changes | Basal: inferior and inferolateral | All basals | No changes |
| Mid: inferior, inferolateral | |||||
| Apical: inferior, lateral | |||||
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Puchalski, M.; Kamińska, H.; Bartoszek, M.; Brzewski, M.; Werner, B. COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up. Int. J. Environ. Res. Public Health 2022, 19, 3456. https://doi.org/10.3390/ijerph19063456
AMA Style
Puchalski M, Kamińska H, Bartoszek M, Brzewski M, Werner B. COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up. International Journal of Environmental Research and Public Health. 2022; 19(6):3456. https://doi.org/10.3390/ijerph19063456
Chicago/Turabian StylePuchalski, Mateusz, Halszka Kamińska, Marta Bartoszek, Michał Brzewski, and Bożena Werner. 2022. "COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up" International Journal of Environmental Research and Public Health 19, no. 6: 3456. https://doi.org/10.3390/ijerph19063456
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
